Bevacizumab treatment for human glioblastoma. Can it induce cognitive impairment?. Issue 5 (May 2014)

• Record Type: Journal Article
• Authors: Pakzad, Ashraf; Obad, Nina; Espedal, Heidi; Stieber, Daniel; Keunen, Olivier; Sakariassen, Per Ø.; Niclou, Simone P.; Bjerkvig, Rolf
• Is Part Of: Neuro-oncology. Volume 16:Issue 5(2014:May)
• Page Start: 754
• Page End: 756
• Publication Date: 2014-05
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/nou013
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: Recent results from 2 double-blind, placebo-controlled phase III trials (RTOG 0825) and (AVAglio) for first-line treatment of glioblastoma patients with the VEGF antibody bevacizumab, showed similar results, related to overall and progression-free survival. The RTOG 0825 trial indicated, opposed to the AVAglio trial, that patients treated with bevacizumab showed a decline in global neurocognitive function compared to untreated patients, -a decline that was most obvious after prolonged treatment. At present, there is a considerably controversy related to these observations. In the present work we point at the possibility that bevacizumab treatment of the normal brain can reduce synaptic plasticity in the hippocampus. We believe that such a phenomenon may partly explain the reduced cognitive function observed in patients in the RTOG 0825 trial. Since the same effects were not clearly defined in the AVAglio trial, further studies on putative neurocognitive effects after bevacizumab treatment are warranted.